Related Experiment Video
Updated: Aug 10, 2026
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Cellular immunotherapy with dendritic cells in cancer: current status
Alessio Nencioni1, Peter Brossart
1Massachusetts Institute of Technology, Center for Cancer Research, Cambridge, USA.
Stem Cells (Dayton, Ohio)
|July 28, 2004
Summary
Dendritic cells (DCs) are immune cells that can be generated to fight cancer. While safe and effective at generating immune responses, clinical benefits are limited in patients with advanced disease.
Area of Science:
- Immunology
- Cellular Therapy
- Cancer Research
Background:
- Dendritic cells (DCs) are key antigen-presenting cells that initiate antigen-specific immune responses.
- DCs can be generated ex vivo from hematopoietic stem cells using cytokine cocktails.
- DCs have been investigated in clinical trials for cancer immunotherapy.
Purpose of the Study:
- To review the current applications and potential of dendritic cells in cancer immunotherapy.
- To evaluate the safety and immunogenicity of DCs pulsed with tumor antigens.
- To identify factors limiting clinical efficacy and suggest future directions for DC-based therapies.
Main Methods:
- Ex vivo generation of DCs from monocytes or stem cells.
- Administration of tumor antigen-pulsed DCs in cancer patients.
- Assessment of safety, immune response, and clinical outcomes.
Main Results:
- DC administration is safe and elicits antigen-specific immune responses.
- Clinical responses observed in a subset of patients.
- Efficacy may be limited by factors such as prior treatments and tumor burden.
Conclusions:
- Dendritic cell therapy shows promise for cancer treatment, particularly in earlier disease stages or as adjuvant therapy.
- Further research is needed to optimize patient selection and treatment protocols.
- DCs represent a valuable cellular immune adjuvant with potential in various immunotherapy settings.
Related Concept Videos
01:40Cell-mediated Immune Responses
Overview
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...